UM  > 中華醫藥研究院
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
Tang, Zheng-Hai; Lu, Jin-Jian
2018
Source PublicationCANCER LETTERS
ISSN0304-3835
Volume420Pages:242-246
Abstract

Given the successful identification of epidermal growth factor receptor EGFR T790M, the third generation EGFR tyrosine kinase inhibitor (TKI), osimertinib (OSI, AZD9291), was developed to target EGFR T790M mutation. OSI was approved for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation. However, the disease would progress after the patient received OSI treatment for approximately 10 months. Resistance mechanisms to OSI, such as additional mutation of EGFR and alternative kinase activation, were recently identified, and some novel therapeutic strategies were proposed to overcome OSI resistance. In this review, the resistance mechanisms and therapeutic strategies for OSI-resistant NSCLC were summarized to direct further use of OSI and aid in the development of novel drugs or strategies for OSI-resistant NSCLC. (C) 2018 Elsevier B.V. All rights reserved.

KeywordOsimertinib Azd9291 Egfr Tki Resistant Mechanisms Therapeutic Strategies
DOI10.1016/j.canlet.2018.02.004
URLView the original
Indexed BySCI
Language英语
WOS Research AreaOncology
WOS SubjectOncology
WOS IDWOS:000428098200025
PublisherELSEVIER IRELAND LTD
The Source to ArticleWOS
Fulltext Access
Citation statistics
Cited Times [WOS]:20   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionInstitute of Chinese Medical Sciences
AffiliationState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China
First Author AffilicationInstitute of Chinese Medical Sciences
Recommended Citation
GB/T 7714
Tang, Zheng-Hai,Lu, Jin-Jian. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies[J]. CANCER LETTERS,2018,420:242-246.
APA Tang, Zheng-Hai,&Lu, Jin-Jian.(2018).Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies.CANCER LETTERS,420,242-246.
MLA Tang, Zheng-Hai,et al."Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies".CANCER LETTERS 420(2018):242-246.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Tang, Zheng-Hai]'s Articles
[Lu, Jin-Jian]'s Articles
Baidu academic
Similar articles in Baidu academic
[Tang, Zheng-Hai]'s Articles
[Lu, Jin-Jian]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Tang, Zheng-Hai]'s Articles
[Lu, Jin-Jian]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.